Kalaris Therapeutics Ownership | Who Owns Kalaris Therapeutics?

Kalaris Therapeutics Ownership Summary

Kalaris Therapeutics is owned by 4.00% institutional investors, 12.59% insiders, and 83.41% retail investors. Samsara biocapital is the largest institutional shareholder, holding 61.22% of KLRS shares.

KLRS Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Kalaris Therapeutics	4.00%	12.59%	83.41%
Sector	Healthcare Stocks	232.20%	10.74%	-142.94%
Industry	Biotech Stocks	382.11%	10.55%	-292.66%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Samsara biocapital	11.45M	61.22%	$66.17M
Tang capital management	418.24K	2.24%	$2.42M
Siren	318.26K	1.70%	$1.84M
Vanguard group	292.79K	1.57%	$2.47M
Woodline partners lp	241.10K	1.29%	$1.39M
Renaissance	87.75K	0.47%	$740.62K
Redmile group	82.95K	0.44%	$479.48K
Geode capital management	82.65K	0.44%	$697.60K
Propel bio management	42.05K	0.22%	$354.93K
Squarepoint ops	40.17K	0.21%	$232.20K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Samsara biocapital	11.45M	8.64%	$66.17M
Propel bio management	42.05K	0.30%	$354.93K
Tang capital management	418.24K	0.09%	$2.42M
Siren	318.26K	0.07%	$1.84M
Fortis capital advisors	40.00K	0.05%	$337.60K
Redmile group	82.95K	0.05%	$479.48K
Nano cap new millennium growth fund l p	4.00K	0.03%	$33.76M
Belpointe asset management	40.00K	0.01%	$337.60K
Woodline partners lp	241.10K	0.01%	$1.39M
Keel point	10.22K	0.01%	$86.30K

Top Buyers

Holder	Shares	% Assets	Change
Woodline partners lp	241.10K	0.01%	241.10K
Vanguard group	292.79K	-	89.74K
Tang capital management	418.24K	0.09%	57.38K
Propel bio management	42.05K	0.30%	42.05K
Siren	318.26K	0.07%	35.68K

Top Sellers

Holder	Shares	% Assets	Change
Octagon capital advisors lp	-	-	-360.00K
Gilead sciences	-	-	-317.79K
Ecor1 capital	-	-	-201.72K
Renaissance	87.75K	0.00%	-25.00K
Xtx topco	-	-	-24.23K

New Positions

Holder	Shares	% Assets	Change	Value
Propel bio management	42.05K	0.30%	42.05K	$354.93K
Jane street group	33.11K	-	33.11K	$279.48K
Bridgeway capital management	22.50K	0.00%	22.50K	$130.05K
Simplify asset management	20.07K	0.00%	20.07K	$169.43K
Keel point	10.22K	0.01%	10.22K	$86.30K

Sold Out

Holder	Change
Eversource wealth advisors	-30.00
Farther finance advisors	-33.00
Coldstream capital management	-208.00
Strengthening families & communities	-268.00
Federated hermes	-578.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	19	-38.71%	748,273	-94.34%	4	0.08%	11	-35.29%	4	-20.00%
Sep 30, 2025	11	-62.07%	388,919	-97.09%	2	0.04%	7	-41.67%	2	-71.43%
Jun 30, 2025	29	-6.45%	13,362,268	-3.69%	329	5.99%	12	-61.29%	7	-
Mar 31, 2025	31	-	13,874,350	-	74	-	31	-	-	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Dec 18, 2025	AKKARAJU SRINIVAS		Buy	$5.00M
Mar 26, 2025	Hagen Brett R	Chief Accounting Officer	Sell	$8.14K

Insider Transactions Trends

Date	Buy	Sell
2025 Q4	-	-
2025 Q2	-	-
2025 Q1	-	1

KLRS Ownership FAQ

Who Owns Kalaris Therapeutics?

Kalaris Therapeutics shareholders are primarily institutional investors at 4.00%, followed by 12.59% insiders and 83.41% retail investors. The average institutional ownership in Kalaris Therapeutics's industry, Biotech Stocks , is 382.11%, which Kalaris Therapeutics falls below.

Who owns the most shares of Kalaris Therapeutics?

Kalaris Therapeutics’s largest shareholders are Samsara biocapital (11.45M shares, 61.22%), Tang capital management (418.24K shares, 2.24%), and Siren (318.26K shares, 1.70%). Together, they hold 65.15% of Kalaris Therapeutics’s total shares outstanding.

Does Blackrock own Kalaris Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Kalaris Therapeutics.

Who is Kalaris Therapeutics’s biggest shareholder by percentage of total assets invested?

Samsara biocapital is Kalaris Therapeutics’s biggest shareholder by percentage of total assets invested, with 8.64% of its assets in 11.45M Kalaris Therapeutics shares, valued at 66.17M$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools